Phase I Trial of Daily Oral Polyphenon E in Patients With Asymptomatic Rai Stage 0 to II Chronic Lymphocytic Leukemia

PURPOSE: To define the optimal dose of Polyphenon E for chronic daily administration and tolerability in patients with chronic lymphocytic leukemia (CLL). PATIENTS AND METHODS: Previously untreated patients with asymptomatic Rai stage 0 to II CLL were eligible for participation. Polyphenon E with a...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Shanafelt, Tait D., Call, Tim G., Zent, Clive S., LaPlant, Betsy, Bowen, Deborah A., Roos, Michelle, Secreto, Charla R., Ghosh, Asish K., Kabat, Brian F., Lee, Mao-Jung, Yang, Chung S., Jelinek, Diane F., Erlichman, Charles, Kay, Neil E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2009
Gaiak:
Original Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2727287/
https://ncbi.nlm.nih.gov/pubmed/19470922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.21.1284
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak